Cocrystal Pharma (NASDAQ:COCP) Stock, Quote.Headers.trade-ideas

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

StockMarket analysts

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

COCP

SNOW

URBN

Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Penny Stocks

Movers

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company completed a $4 million private placement.

Why Cocrystal Pharma Shares Are Trading Higher Today

Small Cap

Intraday Update

AMBO

APLM

AREB

AREN

ARVL

AUDC

BRFH

BTTX

CADL

CLXT

EBIX

ELEV

ELOX

EOSE

GCTK

GFAI

GRVY

JFBR

KSPN

LTRY

MGNX

MICS

MSGM

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

OCTO

ONCS

OUST

PEAR

PLXP

PXMD

SECO

Syneos Health, Inc. - Class A Common Stock

SYNH

TGTX

TRKA

UFAB

VORB

WDFC

Gainers


	PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.


Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Cocrystal Pharma Inc

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Overweight and maintains $160 price target.</p>


Reiteration

DASH

Cantor Fitzgerald Reiterates Overweight on DoorDash, Maintains $160 Price Target

<p><strong>Ideaya Biosciences Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a precision medicine oncology company, released interim Phase 2 <a href="https://www.benzinga.com/pressreleases/24/09/n40975957/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-and-successful-fda-typ">clinical trial data</a>.</p>
<p>The data centers on darovasertib in neoadjuvant (therapy before surgery) for uveal melanoma (UM) and an FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM. </p>
<p>Uveal melanoma is the most common type of eye cancer in adults. Darovasertib is currently being evaluated in four ongoing clinical trials, two of which are in collaboration with <strong>Pfizer Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39670897/ideaya-biosciences-highlights-encouraging-preliminary-efficacy-safety-profile-for-patients-with-h" rel="noreferrer noopener">IDEAYA Biosciences Highlights &#8216;Encouraging&#8217; Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer</a>.</strong></p>
<p>The report shows:</p>
<ul>
<li>Approximately 49% of patients demonstrated greater than 30% tumor shrinkage and approximately 61% eye preservation rate for enucleation patients. </li>
<li>Darovasertib data show that approximately 49% of patients demonstrate greater than 30% tumor shrinkage and approximately 61% eye preservation rate for enucleation patients.</li>
<li>Around 59% of patients showed greater than 20% ocular tumor shrinkage.</li>
</ul>
<p>Ideaya is targeting to initiate a potential registration-enabling Phase 3 randomized clinical trial in neoadjuvant UM patients following finalization of the clinical protocol with the FDA. </p>
<p>The randomized Phase 3 clinical trial design incorporates guidance and feedback from the U.S. FDA following a recent Type C meeting.&nbsp;</p>
<p>In the Phase 3 clinical trial, the company projects that approximately 400 patients will be randomized to receive darovasertib in either the treatment arm or the control arm, with potential modifications pending further FDA feedback.</p>
<p><strong>Price Action: </strong>Ideaya stock is down 5.3% at $33.14 per share at last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/09/40977596/latest-trial-setback-for-astrazenecas-dato-dxd-the-drug-fails-to-extend-lives-of-pretreated-breas" target="_blank" rel="noreferrer noopener">Latest Trial Setback For AstraZeneca&#8217;s Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients</a>.</strong></li>
</ul>


Biotech

Health Care

General

IDYA

Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate

<h3 class="wp-block-heading">When Can We Take Profits?&nbsp;</h3>
<p>On Friday morning, I got a question from a subscriber:&nbsp;</p>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><p>Where does this need to go to make the trade profitable? Current stock is $201.33</p>
</blockquote>
<p>The trade he was referring to was&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial">our call spread</a>&nbsp;on&nbsp;<strong>Powell Industries, Inc. </strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>). That&#8217;s a small cap industrial that&#8217;s essentially a picks &amp; shovels play on increased demand for energy.&nbsp;</p>
<p><figure class="wp-block-image aligncenter size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial"><img loading="lazy" decoding="async" width="837" height="766" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082514/POWL-.jpg" alt="" class="wp-image-1367" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082514/POWL-.jpg 837w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082514/POWL--300x275.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082514/POWL--768x703.jpg 768w" sizes="(max-width: 837px) 100vw, 837px" /></a><figcaption class="wp-element-caption"><em>Click on the factory to go to the post.</em></figcaption></figure></p>
<p>Our trade on POWL last month was a vertical spread expiring on December 20th, buying the $185 strike calls and selling the $190 strike calls, for a net debit of $1.60. If the stock closes above $190 on December 20th, that spread will expire at its maximum value of $5. In that case, we will have made a 213% gain on the $1.60 we paid for it.&nbsp;</p>
<p>My answer to my subscriber was that we could exit our POWL trade now for a profit. But we&#8217;d probably only get close to a 100% gain on it. That&#8217;s because we were so far from the expiration date. That&#8217;s really the main con of call spreads.&nbsp;</p>
<h3 class="wp-block-heading">The Pros And Cons Of Call Spreads</h3>
<p>The main con here is that the short call leg reduces your gains if you try to sell it early. Even though POWL closed at&nbsp;$206.34&nbsp;on Friday&#8211;well above the price where our max again occurs ($190), we wouldn&#8217;t be able to sell this call spread for a net credit of $5 today. We might be able to sell it for $3.20 (which would still be a 100% gain on the $1.60 we paid). But if we want the full, 200%+ gain, we need to hope the stock stays above $190 until we get closer to that December expiration date.&nbsp;</p>
<h3 class="wp-block-heading">So Why Do Call Spreads?</h3>
<p>The first pro of call spreads is that, like other options trades, you can make a lot more money than a shareholder on the same movement in the underlying stock. When we entered our call spread on Powell Industries, on August 13th, the stock was trading at about $162. It only needs to be trading 17% higher than that on December 20th, for us to make more than 200% on this trade.&nbsp;</p>
<p>The second pro of call spreads is that they are cheaper than just buying a call option. That&#8217;s particularly true when you&#8217;re dealing with stocks that have high dollar prices per share. Just buying the $190 strike calls on Powell Industries last month, might have cost over $20 per contract, but with the call spread, we knocked that down to $1.60.&nbsp;</p>
<p>Finally, another pro of call spreads is that having a short leg of the trade helps you avoid IV crush when you are betting on a stock shortly before it releases earnings. Implied volatility drops after earnings releases, lowering the value of options expiring soon after. But with a call spread, IV crush lowering the value of the short call can offset the impact of it lowering the value of your long call.&nbsp;</p>
<h3 class="wp-block-heading">A Great Tool If You&#8217;re Aware Of The Pros And Cons</h3>
<p>Call spreads are a great tool to have in your trading tool box, as long as you&#8217;re aware of the tradeoffs. In the case of Powell Industries, the reason we went out to December 20th with that trade was because the next time the company releases earnings is in early December. And December 20th was the soonest expiration afterwards. Given the company&#8217;s attractive valuation and macro tailwinds with energy demand, there&#8217;s a good chance we&#8217;ll get close to a max profit on this trade.&nbsp;</p>
<p>If you want a heads up when we place a trade on the next name we find with similar characteristics to Powell Industries, feel free to subscribe to our trading Substack/occasional email list below.&nbsp;</p>
<p><em>If you&#8217;d like to stay in touch</em></p>
<p>You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;<strong>create hedged portfolios</strong>&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (<strong>we&#8217;re using that for our occasional emails now</strong>).</p>
<p><figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082631/Widget-1.jpg" alt="" class="wp-image-1368" style="width:602px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082631/Widget-1.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/21082631/Widget-1-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></figure></p>
<p>And you can hedge your long positions using our&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">optimal hedging app</a>.&nbsp;</p>


Options

Opinion

POWL

The Pros And Cons Of Call Spreads

<p>-2024 Bank of America European Autos and Future Car Virtual Conference&nbsp;&nbsp;&nbsp;&nbsp;</p>


STLA

Stellantis CFO Says Our Target Is To Cut Inventories In North America By 100,000 Units By Start Of 2025

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Overweight and maintains $45 price target.</p>


CART

Cantor Fitzgerald Reiterates Overweight on Maplebear, Maintains $45 Price Target

<p><strong>High-performance, compact power supply family meets stringent medical equipment safety standards without custom designs</strong></p>
<p>Advanced Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) – a global leader in highly engineered, precision power conversion, measurement and control solutions – has announced the NCF150 series of high-isolation, low-leakage current AC-DC power supplies that enable medical equipment designers to meet the cardiac floating (CF) requirements of the IEC 60601-1 medical safety standard using off-the-shelf products.</p>
<p>Type CF is the most stringent medical electrical safety classification and is essential for medical products that may come in direct contact with the heart, including dialysis machines, cardiac-related systems and platforms for electrosurgery. With the launch of its SL Power NCF150 series of CF-rated AC-DC power supplies, Advanced Energy now offers standard, compact products that combine the performance and reliability demanded by complex medical systems with the high isolation voltage and low leakage current essential for CF certification.</p>
<p><br />&nbsp;</p>


AEIS

Advanced Energy Launches World's First Off-The-Shelf Convection Cooled CF-Rated Standard Power Supplies which Meets Stringent Medical Equipment Safety Standards Without Custom Designs

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Neutral and maintains $3590 price target.</p>


BKNG

Cantor Fitzgerald Reiterates Neutral on Booking Holdings, Maintains $3590 Price Target

Treasure Global Shares Resume Trade

KAVL

Kaival Brands Innovations Group Shares Resume Trading

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and maintains $230 price target.</p>


AMZN

Cantor Fitzgerald Reiterates Overweight on Amazon.com, Maintains $230 Price Target

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Arista Networks</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for <strong>Arista Networks</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $81,600, and 9, calls, for a total amount of $701,394.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $350.0 to $400.0 for Arista Networks over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Arista Networks's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Arista Networks's significant trades, within a strike price range of $350.0 to $400.0, over the past month.</p>
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100098_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$33.4</td>
<td>$29.9</td>
<td>$32.0</td>
<td>$355.00</td>
<td>$288.0K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$19.0</td>
<td>$18.1</td>
<td>$18.41</td>
<td>$380.00</td>
<td>$138.0K</td>
<td style="text-align: right;">502</td>
<td style="text-align: right;">170</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$40.8</td>
<td>$39.9</td>
<td>$40.8</td>
<td>$390.00</td>
<td>$81.6K</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$15.0</td>
<td>$13.2</td>
<td>$14.2</td>
<td>$390.00</td>
<td>$71.0K</td>
<td style="text-align: right;">83</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$50.6</td>
<td>$49.1</td>
<td>$49.7</td>
<td>$360.00</td>
<td>$49.7K</td>
<td style="text-align: right;">380</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Arista Networks</h3>
<p>Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.</p>
<p>Having examined the options trading patterns of Arista Networks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Arista Networks</h3>
<ul>
<li>With a volume of 193,912, the price of ANET is down -0.32% at $383.23. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>What The Experts Say On Arista Networks</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $384.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Arista Networks with a target price of $400.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on Arista Networks, maintaining a target price of $369. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Arista Networks with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


ANET

Decoding Arista Networks's Options Activity: What's the Big Picture?

<p><a href="https://hntrbrk.com/winnebago/" title="https://hntrbrk.com/winnebago/">https://hntrbrk.com/winnebago/</a></p>


Short Sellers

Watching Winnebago Industries; Hunterbrook Issues Report On Co Titled ""Grand Deception" — Winnebago Muzzles Outcry Over Major Problem That Owners Say Makes RVs Dangerous, Untowable, Worthless"

<p>19 analysts have shared their evaluations of Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.53, a high estimate of $35.00, and a low estimate of $20.00. This upward trend is apparent, with the current average reflecting a 23.03% increase from the previous average price target of $23.19.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100060_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Zeta Global Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Zach Cummins</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Zach Cummins</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zeta Global Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zeta Global Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Zeta Global Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Zeta Global Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZETA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Zeta Global Holdings analyst ratings.</strong></a></p>
<h2>Delving into Zeta Global Holdings's Background</h2>
<p>Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.</p>
<h3>Zeta Global Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Zeta Global Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>32.61%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Zeta Global Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-12.32%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Zeta Global Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-13.74%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.95%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.85</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ZETA

Breaking Down Zeta Global Holdings: 19 Analysts Share Their Views

<p>20 analysts have expressed a variety of opinions on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $273.75, a high estimate of $317.00, and a low estimate of $190.00. This current average represents a 2.96% decrease from the previous average price target of $282.10. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100049_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Biogen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$302.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$244.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Biogen. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Biogen compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Biogen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Biogen analyst ratings.</strong></a></p>
<h2>All You Need to Know About Biogen</h2>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<h3>Breaking Down Biogen's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Biogen's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>0.36%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.68%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Biogen's ROE excels beyond industry benchmarks, reaching <strong>3.75%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Biogen's ROA excels beyond industry benchmarks, reaching <strong>2.19%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Biogen's debt-to-equity ratio is below the industry average at <strong>0.42</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BIIB

Forecasting The Future: 20 Analyst Projections For Biogen

<p>Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) underwent analysis by 31 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $80.55, a high estimate of $90.00, and a low estimate of $71.00. Observing a 7.73% increase, the current average has risen from the previous average price target of $74.77. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100038_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Walmart among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$76.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joe Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joe Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$71.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Walmart. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Walmart compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Walmart's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Walmart's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WMT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Walmart analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Walmart</h2>
<p>Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 stores globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.</p>
<h3>Walmart's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Walmart's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of <strong>4.77%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Walmart's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.66%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Walmart's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.43%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Walmart's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Walmart's debt-to-equity ratio is below the industry average at <strong>0.73</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 31 Analyst Ratings For Walmart

<p>Analysts' ratings for State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for State Street, revealing an average target of $89.07, a high estimate of $103.00, and a low estimate of $73.00. Marking an increase of 3.05%, the current average surpasses the previous average price target of $86.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100028_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive State Street. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$79.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Steven Chubak</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$84.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to State Street. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of State Street compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for State Street's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of State Street's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on State Street analyst ratings.</strong></a></p>
<h2>Discovering State Street: A Closer Look</h2>
<p>State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $42 trillion in assets under custody and administration and $4.1 trillion assets under management as of Dec. 31, 2023, State Street operates globally in more than 100 geographic markets and employs more than 46,000 worldwide.</p>
<h3>Understanding the Numbers: State Street's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> State Street's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>2.6%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>20.53%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> State Street's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.96%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.2%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.49</strong>, State Street faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into State Street Stock: Analyst Perspectives (15 Ratings)

<p>Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) has outperformed the market over the past 5 years by 15.91% on an annualized basis producing an average annual return of 29.92%. Currently, Zscaler has a market capitalization of $26.22 billion. </p>
<p><strong>Buying $100 In ZS:</strong> If an investor had bought $100 of ZS stock 5 years ago, it would be worth <strong>$356.67</strong> today based on a price of $173.49 for ZS at the time of writing.</p>
<h3>Zscaler's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100017_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Zscaler 5 Years Ago Would Be Worth This Much Today

<p>8 analysts have expressed a variety of opinions on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Addus HomeCare, presenting an average target of $140.12, a high estimate of $145.00, and a low estimate of $136.00. This upward trend is apparent, with the current average reflecting a 3.9% increase from the previous average price target of $134.86.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100016_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Addus HomeCare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$136.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Addus HomeCare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Addus HomeCare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Addus HomeCare analyst ratings.</strong></a></p>
<h2>Get to Know Addus HomeCare Better</h2>
<p>Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.</p>
<h3>Addus HomeCare's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Addus HomeCare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.36%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Addus HomeCare's net margin excels beyond industry benchmarks, reaching <strong>6.3%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Addus HomeCare's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.2%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.7%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Addus HomeCare's debt-to-equity ratio is below the industry average. With a ratio of <b>0.05</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ADUS

Demystifying Addus HomeCare: Insights From 8 Analyst Reviews

<p>Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) has outperformed the market over the past 20 years by 5.46% on an annualized basis producing an average annual return of 13.94%. Currently, Biomarin Pharmaceutical has a market capitalization of $13.44 billion. </p>
<p><strong>Buying $1000 In BMRN:</strong> If an investor had bought $1000 of BMRN stock 20 years ago, it would be worth <strong>$13,575.00</strong> today based on a price of $70.59 for BMRN at the time of writing.</p>
<h3>Biomarin Pharmaceutical's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100012_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BMRN

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today

<p>7 analysts have shared their evaluations of Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Verizon Communications and provided 12-month price targets. The average target is $45.21, accompanied by a high estimate of $51.00 and a low estimate of $42.00. Witnessing a positive shift, the current average has risen by 1.6% from the previous average price target of $44.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100009_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Verizon Communications. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kutgun Maral</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$46.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Philip Cusick</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$46.50</td>
<td>$45.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Verizon Communications. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Verizon Communications compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Verizon Communications's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Verizon Communications's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VZ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Verizon Communications analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Verizon Communications</h2>
<p>Wireless services account for about 70% of Verizon Communications' total service revenue and nearly all of its operating income. The firm serves about 93 million postpaid and 21 million prepaid phone customers (following the acquisition of Tracfone) via its nationwide network, making it the largest US wireless carrier. Fixed-line telecom operations include local networks in the Northeast, which reach about 29 million homes and businesses and serve about 8 million broadband customers. Verizon also provides telecom services nationwide to enterprise customers, often using a mixture of its own and other carriers' networks.</p>
<h3>Verizon Communications: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Verizon Communications's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.61%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>14.0%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Verizon Communications's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.82%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Verizon Communications's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.21%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Verizon Communications's debt-to-equity ratio surpasses industry norms, standing at <strong>1.8</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For Verizon Communications

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price ...

Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)

An update from Cocrystal Pharma (COCP) is now available. Cocrystal Pharma, Inc. recently shared exciting news about their CC-42344 product candidat...

Cocrystal Pharma's Promising Antiviral Candidate for Influenza A

Noble Financial Sticks to Its Buy Rating for Cocrystal Pharma (COCP)

Cocrystal Pharma (COCP) Receives a Buy from Noble Financial

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cocrystal Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cocp-stock-quote/"><strong>COCP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Cocrystal Pharma reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -48 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/cocp-stock-earnings-cocrystal-pharma-for-q2-of-2024/">COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024

Cocrystal Pharma GAAP EPS of -$0.53 misses by $0.03

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and IGM Bi...

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and IGM Biosciences (IGMS)

Cocrystal Pharma (COCP) has issued an update. Cocrystal Pharma, Inc. has announced its plans to participate in upcoming investment conferences, sig...

Cocrystal Pharma Engages Investors at Upcoming Conferences

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price t...

Buy Rating Affirmed for Cocrystal Pharma Amid Promising Drug Pipeline and Strong Clinical Results

AMAT

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

CSCO

CTRM

ESPR

GLNG

GOEV

GOLD

GRAB

HUYA

IGMS

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

NNDM

OGEN

PSFE

RRAC

SACH

STNE

TAYD

TCEHY

TCRT

VUZI

WKHS

XXII

Press Releases

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Events

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Cocrystal Pharma

Cocrystal Pharma (COCP) Forecast

Cocrystal Pharma (NASDAQ:COCP) Stock, Quote.Headers.trade-ideas